Tuberous Sclerosis Complex Clinical Trial
— SOSOfficial title:
The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)
Verified date | August 2020 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to see if simvastatin can be taken safely in patients
with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is
the first step in looking at simvastatin as a drug that may help patients, by impacting the
growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC
patients. The study also seeks to learn more about how simvastatin works, when given to
patients being treated with everolimus or sirolimus, and to evaluate the safety and any
potential benefit to patients taking this 2-drug combination.
The primary objective of this study is to determine the safety of simvastatin in the
treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of
sirolimus or everolimus.
Secondary objectives include:
- To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1).
- To assess the effect of simvastatin on forced vital capacity (FVC).
- To assess the effect of simvastatin on diffusing lung capacity (DLCO).
- To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D)
serum levels.
- To assess the effect of simvastatin with questionnaire- based assessments of dyspnea,
fatigue, and quality of life (QOL).
- Assess signs of clinical benefit.
Status | Completed |
Enrollment | 10 |
Est. completion date | December 13, 2019 |
Est. primary completion date | December 13, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female, age 18 and older with clinically definitive diagnosis (biopsy proven or compatible chest CT/MRI scan) of sporadic LAM (LAM-S) or LAM associated with TS (LAM-TS). - Treated with a stable (at least 3 months) dose of sirolimus or everolimus - Negative pregnancy test (women of child bearing potential) at screening. - Women of childbearing potential must be using barrier, medically acceptable contraceptive precautions. - Signed and dated informed consent. Exclusion Criteria: - Age < 18 years - Known allergy to simvastatin or currently taking simvastatin, or therapy with a medication in the same class as simvastatin within the past 30 days. - Allergy to sirolimus or everolimus. - Current use of other than sirolimus or everolimus investigational drug for TSC or LAM within the past 30 days. - Use of estrogen containing medications, including birth control pills, within the 30 days prior to enrollment. - Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, warfarin, sildenafil or use of strong CYP3A4 inhibitors including gemfibrozil, cyclosporine, danazol, verapamil, diltiazem, and dronedarone. amiodarone, amlodipine, and ranolazine. - Participation in another clinical study(ies) of an investigational treatment or drug within 30 days prior to the screening visit. - Amiodarone; within the past 30 days. - Significant dysfunction of liver (ALT > 2 times upper limit of normal-ULN), kidney (serum creatinine > 1.5 times ULN), or blood (leucopenia (ANC<2000), anemia, Hgb < 11 gm/dl). - History of inflammatory muscle disease or myopathy. - Bleeding diathesis or anticoagulant therapy. - Uncontrolled hyperlipidemia or diabetes. - Pregnant, breast feeding, or plan to become pregnant within the next 6 months - Inadequate contraception (must agree to barrier method) - History of organ transplant. - Active on transplant list. - Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol. - Unstable seizures (recent changes in pattern or anti-epileptics). - Mental illness or cognitive deficit precluding informed consent.. - Inability to attend scheduled clinic visits or comply with study procedures. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | The LAM Foundation |
United States,
Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC. — View Citation
Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840. — View Citation
Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol. 2011 Jun;31(12):2484-98. doi: 10.1128/MCB.01061-10. Epub 2011 Apr 11. — View Citation
Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol. 2012 May;46(5):563-5. doi: 10.1165/rcmb.2011-0381ED. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients | Safety is a primary outcome measure which will be assessed by any major changes or deterioration in patient health. | 5 months | |
Secondary | Percent Predicted FEV1 | Lung function will be measured by FEV1: forced expiratory volume in 1s mean and calculated as % predicted +_ SD (standard deviation). | 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02687633 -
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
|
N/A | |
Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
Recruiting |
NCT01730209 -
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
Recruiting |
NCT04987463 -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
|
Phase 2/Phase 3 | |
Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
Recruiting |
NCT06392009 -
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
Active, not recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 | |
Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|